Michael Nelson is listed as an executive officer, director, and promoter on 5 SEC Form D filings by 2 issuers between Mar 2016 and Jan 2024: Intrommune Therapeutics, Inc. (New York, NY — biotechnology — 2018–2024; $3.28M reported sold to 15 investors) and PalliaTech, Inc. (Albertson, NY — other health care — 2016; $183K reported sold).
What this means 2 separate companies raised money with this person listed as executive officer, director, and promoter, over about 8 years. Across those companies the filings report $3.46M sold in total.
Listed alongside Erick Berglund (4 shared filings), William Reisacher (3 shared filings), Hemanshu Pandya (2 shared filings), Jonathan Rich (2 shared filings), Anthony Robinson (1 shared filing) and 6 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — 1 SEC release, 9 bankruptcy cases matching the name listed in Key records below.
What this means 10 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 5 public filings for Michael Nelson and found 15 differences, 2 worth asking the sponsor about: Regulator action: Continental Stock Transfer and Trust Company, and Michael Nelson (Jan 31, 2003); Form D filed 677 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.